Generic vs. disease-specific patient reported outcome (PRO) instruments for assessing HRQoL burden among patients diagnosed with alopecia areata: Evidence from TARGET-DERM AA.

Challenge

Generic QoL instruments (SF-36, DLQI) may not capture the full psychosocial burden of AA—particularly hair loss-specific distress—yet their comparative performance against disease-specific instruments (AAPPO) in a real-world AA cohort had not been evaluated, creating uncertainty about which PRO instruments to use in AA trials.

Solution

The TARGET-DERM AA registry was used to compare SF-36, DLQI, and AAPPO scores across SALT severity categories, assessing whether each instrument discriminated between mild, moderate, and severe AA using cross-sectional regression and group comparison methods.

Impact

Demonstrating that the SF-36 fails to discriminate AA severity across SALT categories while AAPPO shows meaningful differences supports the selection of disease-specific PRO instruments for AA regulatory submissions and validates AAPPO as the preferred patient-reported endpoint in AA drug development.